source
- Teva reports positive mid-stage results for celiac disease antibody, BioMarin settles patent fight with AscendisTeva said its experimental antibody TEV-408 showed statistically significant and clinically meaningful reduction in gluten-induced intestinal damage in a mid-stage trial for celiac disease. The tr…
- Typewriter secures $56M to advance jumping-gene platform and in vivo CAR-T therapiesTypewriter, a biotech startup, announced it has closed a $56 million financing round. The capital will be used to develop its jumping-gene platform, which seeks to deliver full genes without viral…